Showing 1851-1860 of 3020 results for "".
- Lumenis UltraPulse Technology is Being Used to Treat Kim Phuc “The Girl in the Picture”https://practicaldermatology.com/news/lumenis-ultrapulse-technology-is-being-used-to-treat-kim-phuc-the-girl-in-the-picture/2458821/Lumenis Ltd.’s UltraPulse laser is being used by Jill Waibel, MD to treat scars on Kim Phuc, a survivor of a Vietnam War bombing in 1972. The UltraPulse was chosen for its effectiveness in laser scar revision therapy that is needed to penetrate deep into the thick scars. Kim Phuc, a
- Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel for Crow's Feethttps://practicaldermatology.com/news/revance-therapeutics-initiates-phase-3-clinical-trial-of-botulinum-toxin-type-a-topical-gel-for-crows-feet/2458857/Revance Therapeutics, Inc. has commenced dosing patients in the Phase 3 pivotal study to evaluate the safety and efficacy of its RT001 investigational topical drug product candidate for the treatment of lateral canthal lines, or crow’s feet. The Phase 3 trial will evaluate the safety and ef
- Novartis Drug Odomzo Gains EU Approval for Locally Advanced Basal Cell Carcinomahttps://practicaldermatology.com/news/novartis-drug-odomzo-gains-eu-approval-for-locally-advanced-basal-cell-carcinoma/2458887/Novartis has announced the European Commission approval of Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to cura
- Benzac Skin Refining Mask and Benzac Acne Eliminating Cleanser from Galderma Now Available Nationwidehttps://practicaldermatology.com/news/benzac-skin-refining-mask-and-benzac-acne-eliminating-cleanser-from-galderma-now-available-nationwide/2458893/
- FDA Grants Soligenix Fast Track Designation for SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphomahttps://practicaldermatology.com/news/fda-grants-soligenix-fast-track-designation-for-sgx301-for-first-line-treatment-of-cutaneous-t-cell-lymphoma/2459030/Soligenix, Inc.’s SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) received "fast track" designation from the FDA. Fast track is a designation that the FDA reserves for a drug intended to treat a serious or life-thre
- FDA Grants Bristol-Myers Squibb's Opdivo Accelerated Approval for Melanomahttps://practicaldermatology.com/news/fda-grants-bristol-myers-squibbs-opdivo-accelerated-approval-for-melanoma/2459039/The FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) injection, for intravenous use. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilim
- FDA Grants Breakthrough Status to AD Drug Dupilumabhttps://practicaldermatology.com/news/20141121-fda_grants_breakthrough_status_to_ad_drug_dupilumab/2459056/The FDA has awarded breakthrough therapy designation to the investigational drug dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who had an insufficient response to and/or who are not suitable for topical prescription therapy. Dupilumab blocks IL-4 and IL-13, whi
- Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenuehttps://practicaldermatology.com/news/20141117-actavis_to_acquire_allergan_to_create_top_10_global_growth_pharmaceutical_company_with_23_billion_in_revenue/2459062/Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of A
- Taclonex Granted New Indication for Scalp Plaque Psoriasis in Adolescent Patientshttps://practicaldermatology.com/news/20140930-combination_topical_treatment_approved_for_scalp_plaque_psoriasis_in_adolescent_patients/2459101/LEO Pharma Inc., has received a new indication for Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension for a topical combination treatment of plaque psoriasis of the scalp in patients 12 to 17 years. The new indication represents the first indication for adolescent patients a
- LEO Pharma and KLOX Technologies Strike Global Dermatology Dealhttps://practicaldermatology.com/news/20140715-leo_pharma_and_klox_technologies_strike_global_dermatology_deal/2459167/LEO Pharma A/S and KLOX Technologies Inc. have entered into a worldwide license and joint venture agreement, excluding Canada, to further develop and commercialize KLOX's BioPhotonic technology platform in dermatology, which includes a CE-approved treatment for moderate to sever